Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
14.64
Change:
+ 0.38
Volume:
6,480,900
4:00 PM ET on Jan 27, 2012
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

Jan 5, 2012
Dendreon Announces Fourth Quarter Revenues and Update on Commercialization

Jan 4, 2012
Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference

Dec 6, 2011
Dendreon Agrees to Sell VICTRELIS™ (boceprevir) Royalty Interest for $125 Million



View all »Webcasts

Jan 9, 2012 at 3:30 PM PT
29th Annual J.P. Morgan Healthcare Conference

Dec 6, 2011 at 1:45 PM UK
NASDAQ OMX 27th Investor Program



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com